Genovis acquires IP Rights to novel enzymes for applications within genomics

Today, Genovis has acquired the patent rights to a unique DNA polymerase developed by researchers at Uppsala University. The enzyme has potential applications in research, diagnostics and forensics. 

As a leading developer of enzymes for the life science industry, Genovis has acquired the rights to a new enzyme developed by researchers at Uppsala University, led by Professor Ola Söderberg.

"We have developed a new type of DNA polymerase with properties that could not have arisen naturally. This laboratory-created DNA polymerase opens up fantastic opportunities for biotechnology and medical research”, says Ola Söderberg

The acquisition of the rights gives Genovis exclusive rights to develop and commercialize products based on the DNA polymerase. With the acquisition of the IP rights, Genovis will expand its customer offering to include enzymes in genomics.

"We are excited to have the opportunity to acquire the rights to a unique enzyme with potential uses in several applications within the life science field, from research to diagnostics and forensics. The acquisition follows our strategy to commercialize academic research into high-value products and broaden our offerings", says Fredrik Olsson, CEO of Genovis.

In preparation for the commercialization of the enzyme, Genovis will initiate collaborations with partners as part of the continued product development.